Quick Albuminuria Reduction Key Factor in Finerenone's Efficacy
(MedPage Today) -- Early albuminuria reduction with finerenone (Kerendia) drove protection against chronic kidney disease (CKD) progression in people with type 2 diabetes, according to a post-hoc mediation analysis.
In the pooled analysis using... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 5, 2023 Category: Urology & Nephrology Source Type: news
Albuminuria Reduction Accounts for Much of Finerenone Effect on CKD
MONDAY, Dec. 4, 2023 -- For patients with chronic kidney disease (CKD) and type 2 diabetes, early albuminuria reduction accounts for a large proportion of the treatment effect of finerenone against CKD progression, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 4, 2023 Category: Pharmaceuticals Source Type: news
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Investor Update - December 4, 2023 Category: Pharmaceuticals Source Type: news
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Media News - December 4, 2023 Category: Pharmaceuticals Source Type: news
Antioxidants for adults with chronic kidney disease
Wednesday, November 29, 2023 (Source: Cochrane News and Events)
Source: Cochrane News and Events - November 29, 2023 Category: Information Technology Authors: webteam Source Type: news
Methotrexate Tied to Greater Risks for Older Patients With CKD
(MedPage Today) -- Older patients with chronic kidney disease (CKD) had greater risks for serious adverse events when starting on low-dose methotrexate rather than hydroxychloroquine, a propensity score-matched analysis found.
About 60% of the... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - November 28, 2023 Category: Dermatology Source Type: news
Patients with existing health issues are at a higher risk of sepsis, researchers say
The research found those from deprived communities and victims of health issues such as chronic liver disease and chronic kidney disease were more at risk of developing sepsis (Source: the Mail online | Health)
Source: the Mail online | Health - November 24, 2023 Category: Consumer Health News Source Type: news
Hemoglobin Glycation Index Is Novel Risk Factor for Incident CKD
TUESDAY, Nov. 21, 2023 -- Hemoglobin glycation index (HGI) is a novel risk factor for incident chronic kidney disease (CKD) in the general population, according to a study published online Nov. 1 in the Journal of Clinical Endocrinology&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 21, 2023 Category: Pharmaceuticals Source Type: news
Doppler ultrasound evaluates transplant kidney function
Tuesday, November 28 | 1:50 p.m.-2:00 p.m. | T6-SSGU04-3 | Room N227BAttendees will learn how Doppler ultrasound can image the renal function of transplanted kidneys in this session.Eujin Lee, MD, from Soonchunhyang University Hospital in South Korea will show how drawing a region of interest along the border of a transplanted kidney can measure the vascular index in superb microvascular imaging, is reproducible, and correlates well with estimated glomerular filtration rate (eGFR).Previous research highlights the utility of Doppler ultrasound for measuring the vascular index of lesions in the neck and breast areas. L...
Source: AuntMinnie.com Headlines - November 14, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 2023 Ultrasound Preview Source Type: news
DR ELLIE CANNON: My kidney disease is chronic - so why did my GP not tell me?
DR ELLIE CANNON: I imagine there are many people who are unaware they have been labelled with chronic kidney disease (CKD). (Source: the Mail online | Health)
Source: the Mail online | Health - November 11, 2023 Category: Consumer Health News Source Type: news
Risk Calculator for Early-Stage CKD May Soon Enter US Market Risk Calculator for Early-Stage CKD May Soon Enter US Market
For adults with early-stage chronic kidney disease (CKD), a proprietary formula performed well in stratifying risk of progression to more severe kidney dysfunction and of increased healthcare needs.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2023 Category: Consumer Health News Tags: Nephrology News Source Type: news
Novel Aldosterone Synthase Inhibitor Cuts Albuminuria in Phase II Trial
(MedPage Today) -- PHILADELPHIA -- An oral investigational aldosterone synthase inhibitor (ASI) cut albuminuria by nearly 40% in people in chronic kidney disease (CKD) in a phase II trial.
The 10-mg dose of ASI BI 690517 yielded an average 37... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 7, 2023 Category: Cardiology Source Type: news
ERA and SGLT2 Inhibitor Combo Cuts Albuminuria in Chronic Kidney Disease
(MedPage Today) -- PHILADELPHIA -- A low-dose, investigational endothelin A receptor antagonist paired with an SGLT2 inhibitor reduced albuminuria in patients with chronic kidney disease (CKD) in the phase IIb ZENITH-CKD trial.
By week 12 of... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 5, 2023 Category: Cardiology Source Type: news
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
CAMBRIDGE, Mass., Oct. 25, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the U.S. Food and Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - October 25, 2023 Category: Drugs & Pharmacology Source Type: news
Hope for Patients With T1D and Chronic Kidney Disease Hope for Patients With T1D and Chronic Kidney Disease
Ongoing research promises to reduce inequality in chronic kidney disease outcomes between patients with type 1 diabetes and those with type 2 diabetes.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 23, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
